Jan Philipp Bewersdorf (Jan P Bewersdorf)

Loop profile Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 88

Top Topics

Combination Therapy

Acute Myeloid Leukemia

Stem Cell Transplantation

Top Venues

Leukemia & lymphoma

Expert review of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, Yiwen Liu, Guillaume Berton, Eva J Schaefer, Amer M Zeidan, Aaron Goldberg, Eytan Stein, Guido Marcucci, Rebecca P Bystrom, R Coleman Lindsley, Evan C Chen, Jorge Ramos, Anthony Stein, Vinod A Pullarkat, Ibrahim Aldoss, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Sylvain Garciaz, Brian J Ball, Maximilian Stahl
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study. American journal of hematology 99 (8) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Shai Shimony, Jan Philipp Bewersdorf, Rory Michael Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Evan C Chen, Jorge Ramos Perez, Anthony Stein, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Brian Ball, Maximilian Stahl
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 38 (4) (2024)
Shai Shimony, Jan Philipp Bewersdorf, Rory Michael Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Evan C Chen, Jorge Ramos Perez, Anthony Stein, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Brian Ball, Maximilian Stahl
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia (2024)
Amer M Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonidta Rose, Isaac Boss, Stephanie Halene, Torsten Haferlach, Brian A Fox
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine. Therapeutic advances in hematology 15 (2024)
Amer M Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonidta Rose, Isaac Boss, Stephanie Halene, Torsten Haferlach, Brian A Fox
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine. Therapeutic advances in hematology 15 (2024)
Jan Philipp Bewersdorf, Kishan K Patel, Rory Michael Shallis, Nikolai A Podoltsev, Tariq Kewan, Jessica Stempel, Lourdes Mendez, Maximilian Stahl, Eytan M Stein, Scott F Huntington, George Goshua, Amer M Zeidan
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia. Leukemia & lymphoma (2024)
Amer M Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonidta Rose, Isaac Boss, Stephanie Halene, Torsten Haferlach, Brian A Fox
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine. Therapeutic advances in hematology 15 (2024)
Jan Philipp Bewersdorf, Kishan K Patel, Rory Michael Shallis, Nikolai A Podoltsev, Tariq Kewan, Jessica Stempel, Lourdes Mendez, Maximilian Stahl, Eytan M Stein, Scott F Huntington, George Goshua, Amer M Zeidan
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia. Leukemia & lymphoma 65 (8) (2024)
Jan Philipp Bewersdorf, Kishan K Patel, Rory Michael Shallis, Nikolai A Podoltsev, Tariq Kewan, Jessica Stempel, Lourdes Mendez, Maximilian Stahl, Eytan M Stein, Scott F Huntington, George Goshua, Amer M Zeidan
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia. Leukemia & lymphoma 65 (8) (2024)
Shai Shimony, Jan Philipp Bewersdorf, Rory Michael Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Evan C Chen, Jorge Ramos Perez, Anthony Stein, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Brian Ball, Maximilian Stahl
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 38 (4) (2024)
Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, Yiwen Liu, Guillaume Berton, Eva J Schaefer, Amer M Zeidan, Aaron Goldberg, Eytan Stein, Guido Marcucci, Rebecca P Bystrom, R Coleman Lindsley, Evan C Chen, Jorge Ramos, Anthony Stein, Vinod A Pullarkat, Ibrahim Aldoss, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Sylvain Garciaz, Brian J Ball, Maximilian Stahl
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study. American journal of hematology (2024)
Shai Shimony, Jan Philipp Bewersdorf, Rory Michael Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Evan C Chen, Jorge Ramos Perez, Anthony Stein, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Brian Ball, Maximilian Stahl
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 38 (4) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Jan Philipp Bewersdorf, Kishan K Patel, Rory Michael Shallis, Nikolai A Podoltsev, Tariq Kewan, Jessica Stempel, Lourdes Mendez, Maximilian Stahl, Eytan M Stein, Scott F Huntington, George Goshua, Amer M Zeidan
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia. Leukemia & lymphoma 65 (8) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, Yiwen Liu, Guillaume Berton, Eva J Schaefer, Amer M Zeidan, Aaron Goldberg, Eytan Stein, Guido Marcucci, Rebecca P Bystrom, R Coleman Lindsley, Evan C Chen, Jorge Ramos, Anthony Stein, Vinod A Pullarkat, Ibrahim Aldoss, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Sylvain Garciaz, Brian J Ball, Maximilian Stahl
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study. American journal of hematology 99 (8) (2024)
Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, Yiwen Liu, Guillaume Berton, Eva J Schaefer, Amer M Zeidan, Aaron Goldberg, Eytan Stein, Guido Marcucci, Rebecca P Bystrom, R Coleman Lindsley, Evan C Chen, Jorge Ramos, Anthony Stein, Vinod A Pullarkat, Ibrahim Aldoss, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Sylvain Garciaz, Brian J Ball, Maximilian Stahl
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study. American journal of hematology 99 (8) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Jan Philipp Bewersdorf, Kishan K Patel, Rory Michael Shallis, Nikolai A Podoltsev, Tariq Kewan, Jessica Stempel, Lourdes Mendez, Maximilian Stahl, Eytan M Stein, Scott F Huntington, George Goshua, Amer M Zeidan
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia. Leukemia & lymphoma 65 (8) (2024)
Jan Philipp Bewersdorf, Maximilian Stahl, Justin Taylor, Xiaoli Mi, Namrata Sonia Chandhok, Justin Watts, Andriy Derkach, Mateusz Wysocki, Sydney X Lu, Jessie Bourcier, Simon J Hogg, Jahan Rahman, Sana Chaudhry, Tulasigeri M Totiger, Omar Abdel-Wahab, Eytan M Stein
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia (2023)
Hussein Awada, Carmelo Gurnari, Zhuoer Xie, Jan Philipp Bewersdorf, Amer M Zeidan
What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers 15 (8) (2023)
Jan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E Roe, Jonathan M Irish, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan F Madanat, Joshua F Zeidner, Jessica K Altman, Olatoyosi Odenike, Swaroopa Yerrabothala, Tibor Kovacsovics, Nikolai A Podoltsev, Stephanie Halene, Richard F Little, Richard Piekarz, Steven D Gore, Tae Kon Kim, Amer M Zeidan
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Annals of hematology (2023)
Hussein Awada, Carmelo Gurnari, Zhuoer Xie, Jan Philipp Bewersdorf, Amer M Zeidan
What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers 15 (8) (2023)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Jan Philipp Bewersdorf, Amer M Zeidan
Myeloid-derived suppressor cells: a grey eminence in the AML tumor microenvironment? Expert review of anticancer therapy 22 (3) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Amer M Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonidta Rose, Isaac Boss, Stephanie Halene, Torsten Haferlach, Brian Fox
Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy. Leukemia (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Talha Badar, Mark R Litzow, Rory Michael Shallis, Anand Ashwin Patel, Antoine N Saliba, Madelyn Burkart, Jan Philipp Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin M Abaza, Adam Duvall, Danielle Bradshaw, Vamsi K Kota, Shira Dinner, Aaron D Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer 129 (6) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Talha Badar, Ehab Atallah, Rory M Shallis, Aaron D Goldberg, Anand Ashwin Patel, Yasmin Abaza, Jan Philipp Bewersdorf, Antoine N Saliba, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Adam Duvall, Madelyn Burkart, Maximilian Stahl, Yuanhang Liu, Shira Dinner, Neil Palmisiano, Mark R Litzow, James M Foran
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. American journal of hematology 97 (7) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Jan Philipp Bewersdorf, Rory Michael Shallis, Andriy Derkach, Aaron D Goldberg, Anthony Stein, Eytan M Stein, Guido Marcucci, Amer M Zeidan, Shai Shimony, Daniel J DeAngelo, Richard M Stone, Ibrahim Aldoss, Brian J Ball, Maximilian Stahl
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. Leukemia & lymphoma (2022)
Talha Badar, Mark R Litzow, Rory Michael Shallis, Anand Ashwin Patel, Antoine N Saliba, Madelyn Burkart, Jan Philipp Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin M Abaza, Adam Duvall, Danielle Bradshaw, Vamsi K Kota, Shira Dinner, Aaron D Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer (2022)
Amer M Zeidan, Daniel J DeAngelo, Jeanne Palmer, Christopher S Seet, Martin S Tallman, Xin Wei, Heather Raymon, Priya Sriraman, Stephan Kopytek, Jan Philipp Bewersdorf, Michael R Burgess, Kristen Hege, Wendy Stock
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Annals of hematology 101 (3) (2022)
Yazan Numan, Zaid Abdel Rahman, Justin Grenet, Stephanie Boisclair, Jan Philipp Bewersdorf, Cailin Collins, Dylan Barth, Martina Fraga, Dale L Bixby, Amer M Zeidan, Musa Ylimaz, Pankil Desai, Gabriel Mannis, Yehuda E Deutsch, Yasmin Abaza, Shira Dinner, Olga Frankfurt, Mark R Litzow, Aref Al-Kali, James M Foran, Lisa Z Sproat, Borko Jovanovic, Naval G Daver, Alexander E Perl, Jessica K Altman
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. American journal of hematology 97 (3) (2022)
Talha Badar, Mark R Litzow, Rory Michael Shallis, Anand Ashwin Patel, Antoine N Saliba, Madelyn Burkart, Jan Philipp Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin M Abaza, Adam Duvall, Danielle Bradshaw, Vamsi K Kota, Shira Dinner, Aaron D Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer 129 (6) (2022)
Talha Badar, Mark R Litzow, Rory Michael Shallis, Anand Ashwin Patel, Antoine N Saliba, Madelyn Burkart, Jan Philipp Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin M Abaza, Adam Duvall, Danielle Bradshaw, Vamsi K Kota, Shira Dinner, Aaron D Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer 129 (6) (2022)
Amer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, Mikkael A Sekeres, David P Steensma, Uwe Platzbecker, Sanam Loghavi, Jacqueline Boultwood, Rafael Bejar, John M Bennett, Uma Borate, Andrew M Brunner, Hetty E Carraway, Jane E Churpek, Naval G Daver, Matteo Della Porta, Amy E DeZern, Fabio Efficace, Pierre Fenaux, Maria E Figueroa, Peter Greenberg, Elizabeth A Griffiths, Stephanie Halene, Robert P Hasserjian, Christopher S Hourigan, Nina Kim, Tae Kon Kim, Rami S Komrokji, Vijay Kutchroo, Alan F List, Richard F Little, Ravindra Majeti, Aziz Nazha, Stephen D Nimer, Olatoyosi Odenike, Eric Padron, Mirinal S Patnaik, Gail J Roboz, David A Sallman, Guillermo F Sanz, Maximilian Stahl, Daniel T Starczynowski, Justin Taylor, Zhuoer Xie, Mina L Xu, Michael R Savona, Andrew H Wei, Omar Abdel-Wahab, Valeria Santini
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 36 (12) (2022)
Talha Badar, Mark R Litzow, Rory Michael Shallis, Anand Ashwin Patel, Antoine N Saliba, Madelyn Burkart, Jan Philipp Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin M Abaza, Adam Duvall, Danielle Bradshaw, Vamsi K Kota, Shira Dinner, Aaron D Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer 129 (6) (2022)
Talha Badar, Mark R Litzow, Rory Michael Shallis, Anand Ashwin Patel, Antoine N Saliba, Madelyn Burkart, Jan Philipp Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin M Abaza, Adam Duvall, Danielle Bradshaw, Vamsi K Kota, Shira Dinner, Aaron D Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer 129 (6) (2022)
Xiaoyi Wang, Amer M Zeidan, Rong Wang, Jan Philipp Bewersdorf, Chi Zhang, Nikolai A Podoltsev, Scott F Huntington, Steven D Gore, Xiaomei Ma
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia & lymphoma 62 (10) (2021)
Jan Philipp Bewersdorf, Andriy Derkach, Lohith Gowda, Kamal Menghrajani, Susan DeWolf, Josel D Ruiz, Doris M Ponce, Brian C Shaffer, Roni Tamari, James W Young, Ann A Jakubowski, Boglarka Gyurkocza, Alexander Chan, Wenbin Xiao, Jacob Glass, Amber C King, Sheng F Cai, Anthony Daniyan, Christopher Famulare, Bernadette M Cuello, Nikolai A Podoltsev, Mikhail Roshal, Sergio Giralt, Miguel-Angel Perales, Stuart Seropian, Christina Cho, Amer M Zeidan, Thomas Prebet, Eytan M Stein, Martin S Tallman, Aaron D Goldberg, Maximilian Stahl
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia & lymphoma (2021)
Sonal Agarwal, Andrew Kowalski, Molly Schiffer, Jennifer Zhao, Jan Philipp Bewersdorf, Amer M Zeidan
Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer? Expert review of hematology 14 (2) (2021)
Rory Michael Shallis, Rong Wang, Jan Philipp Bewersdorf, Amer M Zeidan, Amy J Davidoff, Scott F Huntington, Nikolai A Podoltsev, Xiaomei Ma
Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. Therapeutic advances in hematology 12 (2021)
Jan Philipp Bewersdorf, Nishita Parmar, Gary M Israel, Scott N Gettinger, Alfred Ian Lee
Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases. Journal of thrombosis and thrombolysis 52 (3) (2021)
Cecily Allen, Amer M Zeidan, Jan Philipp Bewersdorf
BiTEs, DARTS, BiKEs and TriKEs-Are Antibody Based Therapies Changing the Future Treatment of AML? Life (Basel, Switzerland) 11 (6) (2021)
Molly Schiffer, Jennifer Zhao, Aubrey Johnson, Jane Lee, Jan Philipp Bewersdorf, Amer M Zeidan
The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era. Expert review of anticancer therapy 21 (9) (2021)
Jan Philipp Bewersdorf, Amer M Zeidan
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Cancers 13 (7) (2021)
Russell Lewis, Jan Philipp Bewersdorf, Amer M Zeidan
Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. Cancer management and research 13 (2021)
Rory Michael Shallis, Maximilian Stahl, Wei Wei, Pau Montesinos, Etienne Lengline, Judith Neukirchen, Vijaya R Bhatt, Mikkael A Sekeres, Amir T Fathi, Heiko Konig, Selina Luger, Irum Khan, Gail J Roboz, Thomas Cluzeau, David Martínez-Cuadron, Emmanuel Raffoux, Ulrich Germing, Jayadev Manikkam Umakanthan, Sudipto Mukhereje, Andrew M Brunner, Adam Miller, Christine M McMahon, Ellen K Ritchie, Rebeca Rodríguez-Veiga, Raphaël Itzykson, Blanca Boluda, Florence Rabian, María Del Mar Tormo Díaz, Evelyn Acuña-Cruz, Emma Rabinovich, Brendan Yoo, Isabel Cano, Nikolai A Podoltsev, Jan Philipp Bewersdorf, Steven Gore, Amer M Zeidan
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leukemia & lymphoma 61 (5) (2020)
Jan Philipp Bewersdorf, Amer M Zeidan
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? Leukemia & lymphoma 61 (10) (2020)
Rory Michael Shallis, Maximilian Stahl, Jan Philipp Bewersdorf, Jeanne E Hendrickson, Amer M Zeidan
Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert review of hematology 13 (5) (2020)
Jan Philipp Bewersdorf, Amer M Zeidan
Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes. Cancer 126 (21) (2020)
Jan Philipp Bewersdorf, Rory Michael Shallis, Autumn Diadamo, Lohith Gowda, Nikolai A Podoltsev, Alexa Siddon, Amer M Zeidan
Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought? Leukemia & lymphoma 61 (9) (2020)
Jan Philipp Bewersdorf, Amer M Zeidan
Evolving therapies for lower-risk myelodysplastic syndromes. Annals of hematology 99 (4) (2020)
Jennifer Zhao, Jan Philipp Bewersdorf, Sara Jaszczur, Andrew Kowalski, Sarah Perreault, Molly Schiffer, Steven Gore, Nikolai Podoltsev, Thomas Prebet, Rory Michael Shallis, Amer M Zeidan
High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. Leukemia & lymphoma 62 (5) (2020)
Alexander B Pine, Nora Chokr, Maximilian Stahl, David P Steensma, Mikkael A Sekeres, Mark R Litzow, Selina M Luger, Richard M Stone, Peter L Greenberg, Rafael Bejar, Jan Philipp Bewersdorf, Steven D Gore, Amer M Zeidan
Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leukemia & lymphoma 61 (6) (2020)
Jan Philipp Bewersdorf, Amer M Zeidan
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? Expert review of hematology 13 (10) (2020)
Jan Philipp Bewersdorf, Smith Giri, Martin S Tallman, Amer M Zeidan, Maximilian Stahl
Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-A systematic review and meta-analysis. Transfusion 60 (10) (2020)
Maximilian Stahl, Rory Michael Shallis, Wei Wei, Pau Montesinos, Etienne Lengline, Judith Neukirchen, Vijaya R Bhatt, Mikkael A Sekeres, Amir T Fathi, Heiko Konig, Selina M Luger, Irum Khan, Gail J Roboz, Thomas Cluzeau, David Martínez-Cuadron, Emmanuel Raffoux, Ulrich Germing, Jayadev Manikkam Umakanthan, Sudipto Mukherjee, Andrew M Brunner, Adam Miller, Christine M McMahon, Ellen K Ritchie, Rebeca Rodríguez-Veiga, Raphaël A Itzykson, Blanca Boluda, Florence Rabian, Mar Tormo, Evelyn Acuña-Cruz, Emma Rabinovich, Brendan Yoo, Isabel Cano, Nikolai A Podoltsev, Jan Philipp Bewersdorf, Steven Gore, Amer M Zeidan
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia 34 (12) (2020)
Jan Philipp Bewersdorf, Amer M Zeidan
Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments? Cells 9 (10) (2020)
Jan Philipp Bewersdorf, Rory Michael Shallis, Lohith Gowda, Wei Wei, Karl Hager, Iris Isufi, Tae Kon Kim, Manoj M Pillai, Stuart Seropian, Nikolai A Podoltsev, Steven D Gore, Alexa J Siddon, Amer M Zeidan
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience. Leukemia & lymphoma 61 (9) (2020)
Jan Philipp Bewersdorf, Hetty Carraway, Thomas Prebet
Emerging treatment options for patients with high-risk myelodysplastic syndrome. Therapeutic advances in hematology 11 (2020)
Jan Philipp Bewersdorf, Amer M Zeidan
Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era. Expert review of hematology 13 (11) (2020)
Jan Philipp Bewersdorf, Smith Giri, Rong Wang, Nikolai A Podoltsev, Robert T Williams, Martin S Tallman, Raajit K Rampal, Amer M Zeidan, Maximilian Stahl
Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. Leukemia 35 (6) (2020)
Amer M Zeidan, Xin Hu, Weiwei Zhu, Maximilian Stahl, Rong Wang, Scott F Huntington, Smith Giri, Jan Philipp Bewersdorf, Nikolai A Podoltsev, Steven D Gore, Xiaomei Ma, Amy J Davidoff
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & lymphoma 61 (2) (2019)
Jan Philipp Bewersdorf, Rory Michael Shallis, Rong Wang, Scott F Huntington, Sarah Perreault, Xiaomei Ma, Amer M Zeidan
Healthcare expenses for treatment of acute myeloid leukemia. Expert review of hematology 12 (8) (2019)
Nora Chokr, Alexander B Pine, Jan Philipp Bewersdorf, Rory Michael Shallis, Maximilian Stahl, Amer M Zeidan
Getting personal with myelodysplastic syndromes: is now the right time? Expert review of hematology 12 (4) (2019)
Amer M Zeidan, Nikolai A Podoltsev, Xiaoyi Wang, Jan Philipp Bewersdorf, Rory M Shallis, Scott F Huntington, Steven D Gore, Amy J Davidoff, Xiaomei Ma, Rong Wang
Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis. Cancer 125 (23) (2019)
Rory Michael Shallis, Jan Philipp Bewersdorf, Prajwal C Boddu, Amer M Zeidan
Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia. Expert review of anticancer therapy 19 (8) (2019)
Jan Philipp Bewersdorf, Maximilian Stahl, Amer M Zeidan
Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia? Leukemia & lymphoma 60 (6) (2019)
Jan Philipp Bewersdorf, Rory Shallis, Maximilian Stahl, Amer M Zeidan
Epigenetic therapy combinations in acute myeloid leukemia: what are the options? Therapeutic advances in hematology 10 (2019)
Jan Philipp Bewersdorf, Maximilian Stahl, Amer M Zeidan
Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. Expert review of anticancer therapy 19 (5) (2019)
Jan Philipp Bewersdorf, Sara Mohamed Jaszczur, Salma Afifi, Jennifer C Zhao, Amer M Zeidan
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis. Cancer management and research 11 (2019)
Amy J Davidoff, Xin Hu, Jan Philipp Bewersdorf, Rong Wang, Nikolai A Podoltsev, Scott F Huntington, Steven D Gore, Xiaomei Ma, Amer M Zeidan
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. Leukemia & lymphoma 61 (5) (2019)
Jan Philipp Bewersdorf, Amer M Zeidan
Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes. Leukemia 33 (6) (2019)
Jan Philipp Bewersdorf, Maximilian Stahl, Amer M Zeidan
One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant. Expert review of hematology 12 (8) (2019)
Alexander Loch, Jan Philipp Bewersdorf, Daniel Kofink, Dzafir Ismail, Imran Zainal Abidin, Ramesh Singh Veriah
Generic atorvastatin is as effective as the brand-name drug (LIPITOR®) in lowering cholesterol levels: a cross-sectional retrospective cohort study. BMC research notes 10 (1) (2017)